A successive translational study involved nine mCRPC patients and revealed that [177Lu]Lu-EB-PSMA-617 not only presented increased tumor accumulation but also demonstrated superior therapeutic outcomes compared with [177Lu]Lu-PSMA-617, even with a single imaging dose 68, 69. This evidence concerns the gene FOLH1 and neoplasm.